Skip to content
lifestyle.timesla.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
Lilly declares second-quarter 2026 dividend
May 23, 2026
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 23, 2026
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
May 23, 2026
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
May 22, 2026
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
May 21, 2026
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 21, 2026
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
May 21, 2026
Lilly’s Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
May 19, 2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 16, 2026
Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
May 16, 2026
1
2
3
4
Next Page
→